

## Analysis of *bla*<sub>CTX-M</sub>-Carrying Plasmids from *Escherichia coli* Isolates Collected in the BfT-GermVet Study<sup>▽</sup>

Anne-Kathrin Schink, Kristina Kadlec,\* and Stefan Schwarz

Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut (FLI), Neustadt-Mariensee, Germany

Received 11 March 2011/Accepted 5 June 2011

In this study, 417 *Escherichia coli* isolates from defined disease conditions of companion and farm animals collected in the BfT-GermVet study were investigated for the presence of extended-spectrum  $\beta$ -lactamase (ESBL) genes. Three ESBL-producing *E. coli* isolates were identified among the 100 ampicillin-resistant isolates. The *E. coli* isolates 168 and 246, of canine and porcine origins, respectively, harbored *bla*<sub>CTX-M-15</sub>, and the canine isolate 913 harbored *bla*<sub>CTX-M-15</sub>, as confirmed by PCR and sequence analysis. The isolates 168 and 246 belonged to the novel multilocus sequence typing (MLST) types ST1576 and ST1153, respectively, while isolate 913 had the MLST type ST410. The ESBL genes were located on structurally related IncN plasmids in isolates 168 and 246 and on an IncF plasmid in isolate 913. The *bla*<sub>CTX-M-1</sub> upstream regions of plasmids pCTX168 and pCTX246 were similar, whereas the downstream regions showed structural differences. The genetic environment of the *bla*<sub>CTX-M-15</sub> gene on plasmid pCTX913 differed distinctly from that of both *bla*<sub>CTX-M-1</sub> genes. Detailed sequence analysis showed that the integration of insertion sequences, as well as interplasmid recombination events, accounted for the structural variability in the *bla*<sub>CTX-M</sub> gene regions.

The production of  $\beta$ -lactamases is the predominant resistance mechanism against  $\beta$ -lactam antibiotics in *Enterobacteriaceae*. In contrast to narrow-spectrum  $\beta$ -lactamases, extended-spectrum  $\beta$ -lactamases (ESBLs) are able to hydrolyze the amide bond in the four-membered  $\beta$ -lactam ring of oximino-cephalosporins, such as cefotaxime (4). Nowadays, ESBLs are the major cause of clinical cephalosporin resistance among *Enterobacteriaceae* (24, 27). During recent years, ESBL-producing *Enterobacteriaceae* have been identified not only in the community (11, 20) but also in animals (2, 10, 16, 22, 34). Livermore et al. (20) stated that around the year 2000, dramatic shifts in the prevalence and types of ESBLs among *Enterobacteriaceae* occurred in Europe and that ESBLs of the CTX-M type have become predominant since then. In human isolates, the gene *bla*<sub>CTX-M-15</sub> has spread during recent years through the successful emergence of *E. coli* strains belonging to the multilocus sequence type ST131 (20). A recent study also showed that human pandemic O25:H4-ST131 *E. coli* carrying the *bla*<sub>CTX-M-15</sub> gene emerged among companion animals (14). Although different subtypes of ESBL genes seem to be prevalent in animals and humans, the predominant subtypes detected in members of the *Enterobacteriaceae* from food-producing animals, *bla*<sub>CTX-M-1</sub> and *bla*<sub>CTX-M-2</sub>, were detected in four hospitals in Amsterdam, The Netherlands (1). Animals, especially food-producing animals, have been assumed to represent a reservoir for ESBL-producing bacteria (5), and this observation might suggest a transmission from the animal reservoir to the community. The spread of *bla*<sub>CTX-M</sub> genes was shown to be due mainly to the dissemination of plasmids (10, 12, 24, 32). Thus, the investigation of plasmids is a key com-

ponent for a better understanding of the dissemination and persistence of ESBL genes (6).

To date, little is known about the prevalence of *bla*<sub>CTX-M</sub> genes in *Escherichia coli* strains from food-producing animals or companion animals in Germany. Therefore, the aims of the present study were as follows: (i) to investigate a representative collection of *E. coli* isolates from defined disease conditions of companion and farm animals for the presence of ESBL producers, (ii) to identify the types of ESBL genes present, (iii) to determine the location of the ESBL genes on plasmids or in the chromosomal DNA, and (iv) to sequence the ESBL gene region to gain insight into its organization.

### MATERIALS AND METHODS

**Bacterial isolates and susceptibility testing.** The isolates included in this study originated from the BfT-GermVet monitoring study, which was carried out in Germany during the years 2004 to 2006 (30). In total, 1,626 bacterial isolates collected during these years from defined disease conditions of companion and farm animals have been tested for their susceptibility to 24 antimicrobial agents or combinations of antimicrobial agents by broth microdilution. This collection also included 417 *E. coli* isolates from diseased dogs/cats ( $n = 228$ ), horses ( $n = 102$ ), and swine ( $n = 87$ ) (17). Among them, 100 *E. coli* isolates showed ampicillin resistance. They were from respiratory ( $n = 11$ ), urinary/genital ( $n = 24$ ), or gastrointestinal tract ( $n = 14$ ) infections of cats/dogs, from urinary/genital tract infections, including mastitis-metritis-agalactia syndrome, of swine ( $n = 33$ ), or from genital tract infections of horses ( $n = 18$ ).

To identify potential ESBL producers, the 100 ampicillin-resistant *E. coli* isolates were subjected to an initial ESBL screening for growth in the presence of 1  $\mu$ g/ml cefotaxime and subsequent ESBL phenotypic confirmatory tests as recommended by the Clinical and Laboratory Standards Institute (CLSI) (9).

**Molecular analyses.** The ESBL genes were identified by previously described PCR assays (13) and initially confirmed by sequence analysis of the amplicons. Multilocus sequence typing (MLST) was performed for the *bla*<sub>CTX-M</sub>-positive *E. coli* isolates (36). Plasmids were transferred by conjugation or transformation as previously described (19), with subsequent selection on Luria-Bertani agar supplemented with ampicillin (100  $\mu$ g/ml) or cefotaxime (1  $\mu$ g/ml). Transconjugants and transformants were tested for their antimicrobial susceptibility by broth microdilution according to CLSI recommendations (9). Plasmids were subjected to PCR-based replicon typing (8), and plasmid sizes were determined by S1 nuclease pulsed-field gel electrophoresis (PFGE) using a Chef-DR III system (Bio-Rad, Munich, Germany). The DNA-containing agarose plugs were pre-

\* Corresponding author. Mailing address: Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut (FLI), Höltystr. 10, 31535 Neustadt-Mariensee, Germany. Phone: 49 5034 871 242. Fax: 49 5034 871 246. E-mail: kristina.kadlec@fli.bund.de.

<sup>▽</sup> Published ahead of print on 17 June 2011.

TABLE 1. Characteristics of the three ESBL-producing *E. coli* isolates and their *bla*<sub>CTX-M</sub>-carrying plasmids

| Isolate | Animal species | Disease condition                    | Resistance pattern <sup>a</sup>        | MLST   | ESBL gene                      | ESBL-carrying plasmid | Replicon type | Approximate size (kb) | Colocated resistances <sup>a</sup> |
|---------|----------------|--------------------------------------|--|--------|--------------------------------|-----------------------|---------------|-----------------------|------------------------------------|
| 168     | Dog            | Pneumonia                            | BLA, CHL, ENR, GEN, NEO, SMZ, SXT, TET | ST1576 | <i>bla</i> <sub>CTX-M-1</sub>  | pCTX168               | IncN          | 50                    |                                    |
| 246     | Swine          | Mastitis-metritis-agalactia syndrome | BLA, SMZ, SXT, TET                     | ST1153 | <i>bla</i> <sub>CTX-M-1</sub>  | pCTX246               | IncN          | 50                    |                                    |
| 913     | Dog            | Urinary tract infection              | BLA, CHL, ENR, GEN, NEO, SMZ, SXT, TET | ST410  | <i>bla</i> <sub>CTX-M-15</sub> | pCTX913               | IncF          | 50                    | GEN, TET                           |

<sup>a</sup> BLA,  $\beta$ -lactams; CHL, chloramphenicol; ENR, enrofloxacin; GEN, gentamicin; NEO, neomycin; SMZ, sulfamethoxazole; SXT, sulfamethoxazole-trimethoprim (19:1); TET, tetracycline.

pared as recommended in the PulseNet protocol (29), and the slices were digested with S1 nuclease (Fermentas, St. Leon-Rot, Germany) as described previously (18). The pulse times were increased from 1 to 25 s over 17 h at a voltage of 6 V and an angle of 120°. *Salmonella enterica* serovar Braenderup H9812 digested with XbaI (Fermentas) and the MidRange PFG marker I (New England BioLabs, Frankfurt, Germany) were used as size markers.

The flanking regions of the *bla*<sub>CTX-M</sub> genes were sequenced by primer walking using either the plasmid DNA obtained from the respective transformants and transconjugants or cloned plasmid fragments. For the latter approach, the cloning vector pBluescript(SK+) or pCR-BluntII-TOPO (both from Invitrogen, Groningen, The Netherlands) was used. Sequence comparisons were carried out using the software programs blastn and blastp (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>), the ORF Finder (open reading frame finder) program (<http://www.ncbi.nlm.nih.gov/gorf/gorf.html>), and the IS finder program (<http://www-is.biotoul.fr/is.html>) (all last accessed 18 February 2011).

**Nucleotide sequence accession numbers.** The nucleotide sequences of the *bla*<sub>CTX-M-1</sub> genes, the *bla*<sub>CTX-M-15</sub> gene, and their flanking regions have been deposited in the EMBL database under accession numbers FN806788, FN806790, and FR828676.

## RESULTS AND DISCUSSION

**Presence and types of ESBL genes.** According to their cefotaxime resistance and the subsequent ESBL phenotypic confirmatory tests, three ESBL-producing *E. coli* isolates were identified among the 100 ampicillin-resistant isolates (Table 1). Comparative analysis of the zone diameters of ceftazidime (30  $\mu$ g) and ceftazidime-clavulanic acid (30/10  $\mu$ g), as well as cefotaxime (30  $\mu$ g) and cefotaxime-clavulanic acid (30/10  $\mu$ g), showed a  $\geq 5$ -mm increase in the zone diameter of either antimicrobial agent tested in combination with clavulanic acid versus its zone diameter when tested alone (9). PCR and sequence analysis confirmed that isolate 913 harbored a *bla*<sub>CTX-M-15</sub> gene while the remaining two isolates, 168 and 246, had a *bla*<sub>CTX-M-1</sub> gene.

**Analysis of the *bla*<sub>CTX-M-15</sub> gene region of isolate 913.** *E. coli* 913 was obtained in 2004 from the urine sample of a dog suffering from a urinary tract infection. It showed high MIC values for cefalothin ( $\geq 64$   $\mu$ g/ml), cefazolin ( $\geq 64$   $\mu$ g/ml), cefoperazone ( $\geq 32$   $\mu$ g/ml), ceftiofur ( $\geq 32$   $\mu$ g/ml), and cefquinome ( $\geq 32$   $\mu$ g/ml) and for the non- $\beta$ -lactams chloramphenicol (128  $\mu$ g/ml), enrofloxacin ( $\geq 32$   $\mu$ g/ml), gentamicin (64  $\mu$ g/ml), neomycin (32  $\mu$ g/ml), sulfamethoxazole ( $\geq 2,048$   $\mu$ g/ml), trimethoprim-sulfamethoxazole ( $\geq 64/1,216$   $\mu$ g/ml), and tetracycline ( $\geq 128$   $\mu$ g/ml). The isolate exhibited the MLST type ST410, which belongs to clonal complex 23. *E. coli* isolates of this clonal complex and harboring *bla*<sub>CTX-M-15</sub> genes have been found to be present among human patients in the United States (31) and in Brazil (26) and very recently in clinical and

food samples from Spain (21). In isolate 913, the *bla*<sub>CTX-M-15</sub> gene was located on a plasmid of approximately 50 kb, designated pCTX913, which was transferable by transformation. Replicon typing confirmed that this plasmid belonged to the incompatibility group IncF. The plasmid also conferred resistance to gentamicin and tetracycline.

Sequencing of the *bla*<sub>CTX-M-15</sub> flanking regions revealed the presence of *ISEcp1* in the upstream region. Downstream of the *bla*<sub>CTX-M-15</sub> gene, the terminal 342 bp of a reading frame for a hypothetical protein of 182 amino acids (aa), previously identified on the *bla*<sub>CTX-M-3</sub>-carrying plasmid pCTX-M360 from *Klebsiella pneumoniae* (38), were detected. This segment was followed by a truncated transposase gene, *tnpA*, previously found on the *bla*<sub>TEM-1</sub>-carrying transposon Tn3 (Fig. 1). At the junction of both sequences, a potential recombination site was seen which might have served for a recombination event which led to the truncation of the reading frames of both the hypothetical protein and the Tn3-associated transposase.

A database search revealed that identical sequences downstream of the *bla*<sub>CTX-M-15</sub> gene were present in a wide variety of *bla*<sub>CTX-M-15</sub>-carrying plasmids from *E. coli* (3, 13, 15, 32, 37) and *K. pneumoniae* (33) but also *Enterobacter cloacae* (GenBank accession no. HM204572, 219230) and *Serratia liquefaciens* (GenBank accession no. HM470254). Some of these plasmids were distinctly larger than pCTX913, belonged to different replicon types (including multireplicon types), and conferred additional resistance properties (3, 32, 37). This comparison showed that identical *bla*<sub>CTX-M-15</sub> genes are present in diverse plasmid backgrounds in different members of the *Enterobacteriaceae* from human and animal sources in different countries. Such an observation underlines the enormous flexibility of resistance plasmids to undergo structural changes which might render them resistant to different selective pressures by acquisition of additional resistance genes and able to replicate in different hosts by acquisition of additional replicons.

**Analysis of the *bla*<sub>CTX-M-1</sub> gene regions of isolates 168 and 246.** Isolate 168 was obtained in 2004 from a case of canine pneumonia. It showed high MIC values of amoxicillin combined with clavulanic acid ( $\geq 64/32$   $\mu$ g/ml), cefalothin ( $\geq 64$   $\mu$ g/ml), cefazolin ( $\geq 64$   $\mu$ g/ml), cefoperazone ( $\geq 32$   $\mu$ g/ml), ceftiofur ( $\geq 32$   $\mu$ g/ml), and cefquinome ( $\geq 32$   $\mu$ g/ml) and of chloramphenicol (128  $\mu$ g/ml), enrofloxacin ( $\geq 32$   $\mu$ g/ml), gentamicin (64  $\mu$ g/ml), neomycin (32  $\mu$ g/ml), sulfamethoxazole ( $\geq 2,048$   $\mu$ g/ml), trimethoprim-sulfamethoxazole ( $\geq 64/1,216$






FIG. 2. Schematic presentation of the flanking gene regions of the *bla*<sub>CTX-M-1</sub> genes in plasmids pCTX246 and pCTX168. The open reading frames are shown as arrows, with the arrowhead indicating the direction of transcription. IS elements are shown as boxes. The recombination site between the *mrx* gene and *orf477* is shown between the two maps, while the recombination site that played a role in the truncation of the *mph*(A) gene in pCTX168 is shown below the map of pCTX168. The sequences depicted in these two alignments are from pCTX168 (GenBank accession no. FN806788), pCTX246 (FN806790), pECL0701 (FJ966096), pTZ3509 (AB038042), pSE11-3 (AP009243), and 55989p (CU928159). Vertical bars indicate identical bases compared to the pCTX246 and/or pCTX168 sequences or bases that are identical between the pSE11-3 and 55989p sequences. The areas where the crossovers most likely occurred are indicated by boxes.

upstream of the right-hand IS26 in pCTX246, too, while in pCTX168 the direct repeat was found downstream of the IS26. This observation underlines the structural relatedness of these *bla*<sub>CTX-M-1</sub> gene regions, which have not been found in animal *E. coli* isolates from Germany so far. IncN plasmids carrying the *bla*<sub>CTX-M-1</sub> gene have been described to be transmitted between Danish farm personnel and pigs in different *E. coli* lineages (23). The finding of *bla*<sub>CTX-M-1</sub> genes with similar genetic environments on IncN plasmids in different human,

porcine, and canine *E. coli* isolates from Germany points toward a plasmid transfer among *E. coli* isolates from human and animal sources and a common gene pool for transferable ESBL genes.

ACKNOWLEDGMENTS

We thank Kerstin Meyer and Mike Schiwiek for excellent technical assistance.



This study was supported by internal funding from the Friedrich-Loeffler-Institut (FLI) and is part of the RESET project, financially supported by the German Federal Ministry of Education and Research (BMBF) through the German Aerospace Center (DLR), grant number 01KI1013A (RESET). Anne-Kathrin Schink was supported by a scholarship from the H. Wilhelm Schaumann foundation.

## REFERENCES

1. al Naiemi, N., et al. 2006. Widely distributed and predominant CTX-M extended-spectrum  $\beta$ -lactamases in Amsterdam, The Netherlands. *J. Clin. Microbiol.* **44**:3012–3014.
2. Bortolaia, V., et al. 2010. High diversity of extended-spectrum  $\beta$ -lactamases in *Escherichia coli* isolates from Italian broiler flocks. *Antimicrob. Agents Chemother.* **54**:1623–1626.
3. Boyd, D. A., et al. 2004. Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum  $\beta$ -lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. *Antimicrob. Agents Chemother.* **48**:3758–3764.
4. Bush, K. 2010. Alarming  $\beta$ -lactamase-mediated resistance in multidrug-resistant *Enterobacteriaceae*. *Curr. Opin. Microbiol.* **13**:558–564.
5. Carattoli, A. 2008. Animal reservoirs for extended spectrum  $\beta$ -lactamase producers. *Clin. Microbiol. Infect.* **14**:117–123.
6. Carattoli, A. 2009. Resistance plasmid families in *Enterobacteriaceae*. *Antimicrob. Agents Chemother.* **53**:2227–2238.
7. Carattoli, A., et al. 2010. Complete nucleotide sequence of the IncN plasmid pKOX105 encoding VIM-1, QnrS1 and SHV-12 proteins in *Enterobacteriaceae* from Bolzano, Italy compared with IncN plasmids encoding KPC enzymes in the USA. *J. Antimicrob. Chemother.* **65**:2070–2075.
8. Carattoli, A., et al. 2005. Identification of plasmids by PCR-based replicon typing. *J. Microbiol. Methods* **63**:219–228.
9. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial disk and dilution susceptibility test for bacteria isolated from animals; approved standard, 3rd ed. CLSI document M31-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Cloeckaert, A., et al. 2010. IncII plasmid carrying extended-spectrum- $\beta$ -lactamase gene *bla*<sub>CTX-M-1</sub> in *Salmonella enterica* isolates from poultry and humans in France, 2003 to 2008. *Antimicrob. Agents Chemother.* **54**:4484–4486.
11. Coque, T. M., F. Baquero, and R. Cantón. 2008. Increasing prevalence of ESBL-producing *Enterobacteriaceae* in Europe. *Euro Surveill.* **13**:pii=19051.
12. Coque, T. M., et al. 2008. Dissemination of clonally related *Escherichia coli* strains expressing extended-spectrum  $\beta$ -lactamase CTX-M-15. *Emerg. Infect. Dis.* **14**:195–200.
13. Cullik, A., Y. Pfeifer, R. Prager, H. von Baum, and W. Witte. 2010. A novel IS26 structure surrounds *bla*<sub>CTX-M</sub> genes in different plasmids from German clinical *Escherichia coli* isolates. *J. Med. Microbiol.* **59**:580–587.
14. Ewers, C., et al. 2010. Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum- $\beta$ -lactamase-producing *Escherichia coli* among companion animals. *J. Antimicrob. Chemother.* **65**:651–660.
15. Gangoue-Pieboji, J., et al. 2005. Emergence of CTX-M-15-producing *Enterobacteria* in Cameroon and characterization of a *bla*<sub>CTX-M-15</sub>-carrying element. *Antimicrob. Agents Chemother.* **49**:441–443.
16. Girlich, D., et al. 2007. Extended-spectrum  $\beta$ -lactamase CTX-M-1 in *Escherichia coli* isolates from healthy poultry in France. *Appl. Environ. Microbiol.* **73**:4681–4685.
17. Grobbel, M., et al. 2007. Antimicrobial susceptibility of *Escherichia coli* from swine, horses, dogs and cats as determined in the BfT-GermVet monitoring program 2004–2006. *Berl. Münch. Tierärztl. Wochenschr.* **120**:391–401.
18. Guerra, B., E. Junker, A. Miko, R. Helmuth, and M. C. Mendoza. 2004. Characterization and localization of drug resistance determinants in multidrug-resistant, integron-carrying *Salmonella enterica* serotype Typhimurium strains. *Microb. Drug Resist.* **10**:83–91.
19. Kadlec, K., and S. Schwarz. 2008. Analysis and distribution of class 1 and class 2 integrons and associated gene cassettes among *Escherichia coli* isolates from swine, horses, cats and dogs collected in the BfT-GermVet monitoring study. *J. Antimicrob. Chemother.* **62**:469–473.
20. Livermore, D. M., et al. 2007. CTX-M: changing the face of ESBLs in Europe. *J. Antimicrob. Chemother.* **59**:165–174.
21. López-Cerero, L., et al. 2011. Characterisation of clinical and food animal *Escherichia coli* isolates producing CTX-M-15 extended-spectrum  $\beta$ -lactamase belonging to ST410 phylogroup A. *Int. J. Antimicrob. Agents* **37**:365–367.
22. Meunier, D., E. Jouy, C. Lazizzera, M. Kobisch, and J. Y. Madec. 2006. CTX-M-1- and CTX-M-15-type  $\beta$ -lactamases in clinical *Escherichia coli* isolates recovered from food-producing animals in France. *Int. J. Antimicrob. Agents* **28**:402–407.
23. Moodley, A., and L. Guardabassi. 2009. Transmission of IncN plasmids carrying *bla*<sub>CTX-M-1</sub> between commensal *Escherichia coli* in pigs and farm workers. *Antimicrob. Agents Chemother.* **53**:1709–1711.
24. Naseer, U., and A. Sundsfjord. 31 January 2011. The CTX-M conundrum: dissemination of plasmids and *Escherichia coli* clones. *Microb. Drug Resist.* [Epub ahead of print.] doi:10.1089/mdr.2010.0132.
25. Noguchi, N., K. Takada, J. Katayama, A. Emura, and M. Sasatsu. 2000. Regulation of transcription of the *mph*(A) gene for macrolide 2'-phosphotransferase I in *Escherichia coli*: characterization of the regulatory gene *mphR*(A). *J. Bacteriol.* **128**:5052–5058.
26. Peirano, G., M. D. Asensi, A. Pitondo-Silva, and J. D. D. Pitout. 2011. Molecular characteristics of extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* from Rio de Janeiro, Brazil. *Clin. Microbiol. Infect.* **17**:1039–1043.
27. Pitout, J. D., and K. B. Laupland. 2008. Extended-spectrum  $\beta$ -lactamase-producing *Enterobacteriaceae*: an emerging public health concern. *Lancet Infect. Dis.* **8**:159–166.
28. Oshima, K., et al. 2008. Complete genome sequence and comparative analysis of the wild-type commensal *Escherichia coli* strain SE11 isolated from a healthy adult. *DNA Res.* **15**:375–386.
29. Ribot, E. M., et al. 2006. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of *Escherichia coli* O157:H7, *Salmonella* and *Shigella* for PulseNet. *Foodborne Pathog. Dis.* **3**:59–67.
30. Schwarz, S., et al. 2007. The BfT-GermVet monitoring program—aims and basics. *Berl. Münch. Tierärztl. Wochenschr.* **120**:357–362.
31. Sidjabat, H. E., et al. 2009. Molecular epidemiology of CTX-M-producing *Escherichia coli* isolates at a tertiary medical center in western Pennsylvania. *Antimicrob. Agents Chemother.* **53**:4733–4739.
32. Smet, A., et al. 2010. Complete nucleotide sequence of CTX-M-15-plasmids from clinical *Escherichia coli* isolates: insertional events of transposons and insertion sequences. *PLoS One* **5**:e11202.
33. Soge, O. O., A. M. Queenan, K. K. Ojo, B. A. Adeniyi, and M. C. Roberts. 2006. CTX-M-15 extended-spectrum  $\beta$ -lactamase from Nigerian *Klebsiella pneumoniae*. *J. Antimicrob. Chemother.* **57**:24–30.
34. Tian, G. B., et al. 2009. Detection of CTX-M-15, CTX-M-22, and SHV-2 extended-spectrum  $\beta$ -lactamases (ESBLs) in *Escherichia coli* fecal-sample isolates from pig farms in China. *Foodborne Pathog. Dis.* **6**:297–304.
35. Touchon, M., et al. 2009. Organised genome dynamics in the *Escherichia coli* species results in highly diverse adaptive paths. *PLoS Genet.* **5**:e1000344.
36. Wirth, T., et al. 2006. Sex and virulence in *Escherichia coli*: an evolutionary perspective. *Mol. Microbiol.* **60**:1136–1151.
37. Woodford, N., et al. 2009. Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major *Escherichia coli* lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. *Antimicrob. Agents Chemother.* **53**:4472–4482.
38. Zhu, W. H., et al. 2009. Complete nucleotide sequence of pCTX-M360, an intermediate plasmid between pEL60 and pCTX-M3, from a multidrug-resistant *Klebsiella pneumoniae* strain isolated in China. *Antimicrob. Agents Chemother.* **53**:5291–5292.